BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ashrafizadeh M, Zarrabi A, Hushmandi K, Zarrin V, Moghadam ER, Zabolian A, Tavakol S, Samarghandian S, Najafi M. PD-1/PD-L1 axis regulation in cancer therapy: The role of long non-coding RNAs and microRNAs. Life Sciences 2020;256:117899. [DOI: 10.1016/j.lfs.2020.117899] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
Number Citing Articles
1 Grecea M, Soritau O, Dulf D, Ciuleanu TE, Zdrenghea M. Potential Biomarkers for the Efficacy of PD-1-PD-L Blockade in Cancer. Onco Targets Ther 2021;14:5275-91. [PMID: 34848970 DOI: 10.2147/OTT.S283892] [Reference Citation Analysis]
2 Han X, Liu J, Liu Y, Mou L, Li C. LINC-PINT Inhibited Malignant Progression of Bladder Cancer by Targeting miR-155-5p. Cancer Manag Res 2021;13:4393-401. [PMID: 34103994 DOI: 10.2147/CMAR.S305547] [Reference Citation Analysis]
3 Mirzaei S, Gholami MH, Zabolian A, Saleki H, Farahani MV, Hamzehlou S, Far FB, Sharifzadeh SO, Samarghandian S, Khan H, Aref AR, Ashrafizadeh M, Zarrabi A, Sethi G. Caffeic acid and its derivatives as potential modulators of oncogenic molecular pathways: New hope in the fight against cancer. Pharmacol Res 2021;171:105759. [PMID: 34245864 DOI: 10.1016/j.phrs.2021.105759] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Delfi M, Sartorius R, Ashrafizadeh M, Sharifi E, Zhang Y, De Berardinis P, Zarrabi A, Varma RS, Tay FR, Smith BR, Makvandi P. Self-assembled peptide and protein nanostructures for anti-cancer therapy: Targeted delivery, stimuli-responsive devices and immunotherapy. Nano Today 2021;38:101119. [PMID: 34267794 DOI: 10.1016/j.nantod.2021.101119] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
5 Mirzaei S, Gholami MH, Ang HL, Hashemi F, Zarrabi A, Zabolian A, Hushmandi K, Delfi M, Khan H, Ashrafizadeh M, Sethi G, Kumar AP. Pre-Clinical and Clinical Applications of Small Interfering RNAs (siRNA) and Co-Delivery Systems for Pancreatic Cancer Therapy. Cells 2021;10:3348. [PMID: 34943856 DOI: 10.3390/cells10123348] [Reference Citation Analysis]
6 Anaya-Ruiz M, Perez-Santos M. Small-molecule inhibitor PD-1/PD-L1 interaction for colorectal cancer treatment. Pharm Pat Anal 2021. [PMID: 34875853 DOI: 10.4155/ppa-2021-0016] [Reference Citation Analysis]
7 You L, Wu W, Wang X, Fang L, Adam V, Nepovimova E, Wu Q, Kuca K. The role of hypoxia-inducible factor 1 in tumor immune evasion. Med Res Rev 2021;41:1622-43. [PMID: 33305856 DOI: 10.1002/med.21771] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
8 Gu J, Liu Y, Qi T, Qian W, Hu D, Feng W. Long non-coding RNA DUXAP8 elevates RCN2 expression and facilitates cell malignant behaviors and angiogenesis in cervical cancer via sponging miR-1297. Diagn Pathol 2021;16:105. [PMID: 34774078 DOI: 10.1186/s13000-021-01145-9] [Reference Citation Analysis]
9 Xu Y, Song G, Xie S, Jiang W, Chen X, Chu M, Hu X, Wang ZW. The roles of PD-1/PD-L1 in the prognosis and immunotherapy of prostate cancer. Mol Ther 2021;29:1958-69. [PMID: 33932597 DOI: 10.1016/j.ymthe.2021.04.029] [Reference Citation Analysis]
10 Mirzaei S, Saebfar H, Gholami MH, Hashemi F, Zarrabi A, Zabolian A, Entezari M, Hushmandi K, Samarghandian S, Aref AR, Ashrafizadeh M, Khan H. MicroRNAs regulating SOX2 in cancer progression and therapy response. Expert Rev Mol Med 2021;23:e13. [PMID: 34583803 DOI: 10.1017/erm.2021.15] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Yu Z, Liu Y, Li Y, Zhang J, Peng J, Gong J, Xia Y, Wang L. miRNA-338-3p inhibits glioma cell proliferation and progression by targeting MYT1L. Brain Res Bull 2021;179:1-12. [PMID: 34848272 DOI: 10.1016/j.brainresbull.2021.11.016] [Reference Citation Analysis]
12 Chen L, Musa AE. Boosting immune system against cancer by resveratrol. Phytother Res 2021. [PMID: 34101276 DOI: 10.1002/ptr.7189] [Reference Citation Analysis]
13 Li H, Zheng C, Han J, Zhu J, Liu S, Jin T. PD-1/PD-L1 Axis as a Potential Therapeutic Target for Multiple Sclerosis: A T Cell Perspective. Front Cell Neurosci 2021;15:716747. [PMID: 34381337 DOI: 10.3389/fncel.2021.716747] [Reference Citation Analysis]
14 Bailly C, Thuru X, Quesnel B. Soluble Programmed Death Ligand-1 (sPD-L1): A Pool of Circulating Proteins Implicated in Health and Diseases. Cancers (Basel) 2021;13:3034. [PMID: 34204509 DOI: 10.3390/cancers13123034] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
15 Maloney SM, Hoover CA, Morejon-Lasso LV, Prosperi JR. Mechanisms of Taxane Resistance. Cancers (Basel). 2020;12. [PMID: 33182737 DOI: 10.3390/cancers12113323] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
16 Najafi S, Tan SC, Raee P, Rahmati Y, Asemani Y, Lee EHC, Hushmandi K, Zarrabi A, Aref AR, Ashrafizadeh M, Kumar AP, Ertas YN, Ghani S, Aghamiri S. Gene regulation by antisense transcription: A focus on neurological and cancer diseases. Biomed Pharmacother 2021;145:112265. [PMID: 34749054 DOI: 10.1016/j.biopha.2021.112265] [Reference Citation Analysis]